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were diagnosed during the follow-up period. However, 
both relatives did not display any of the investigated se-
rum antibodies (p = 1).  Discussion: The fi ndings of our 
pilot study argue against a role of serum antibodies as a 
marker of disease susceptibility in fi rst-degree relatives 
of patients with infl ammatory bowel disease. However, 
these data have to await confi rmation in larger ideally 
prospective multicenter studies before defi nite conclu-
sions can be drawn. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 Various serum antibodies have been described to oc-
cur in Crohn’s disease or ulcerative colitis. Although not 
exclusively present in infl ammatory bowel disease, the 
most prominent examples to date are antibodies against 
 Saccharomyces cerevisiae (ASCA) and perinuclear-anti-
neutrophil cytoplasmic autoantibodies (p-ANCA). ASCA 
are regarded as serologic markers for Crohn’s disease and 
can be found in about two thirds of these patients  [1–3] , 
whereas p-ANCA occur in 45 to 80% of patients with ul-
cerative colitis  [4–7] . As opposed to ASCA, which were 
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 Abstract 
 Introduction: Various disease-specifi c serum antibodies 
were described in patients with infl ammatory bowel dis-
ease and their yet healthy fi rst-degree relatives. In the 
latter, serum antibodies are commonly regarded as po-
tential markers of disease susceptibility. The present 
long-term follow-up study evaluated the fate of anti-
body-positive fi rst-degree relatives.  Patients and Meth-
ods: 25 patients with Crohn’s disease, 19 patients with 
ulcerative colitis and 102 fi rst-degree relatives in whom 
presence of ASCA, pANCA, pancreatic- and goblet-cell 
antibodies had been assessed were enrolled. The num-
ber of incident cases with infl ammatory bowel disease 
was compared between antibody-positive and antibody-
negative fi rst-degree relatives 7 years after storage of 
serum samples.  Results: 34 of 102 (33%) fi rst-degree rel-
atives were positive for at least one of the studied serum 
antibodies. In the group of fi rst-degree relatives, one 
case of Crohn’s disease and one case of ulcerative colitis 
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recently described also in association with HLA-B27 as-
sociated spondylarthropathies  [8, 9] , antibodies against 
exocrine pancreas (PAB) are highly disease-specifi c  [10] , 
but are present only in about one third of patients with 
Crohn’s disease  [11] . Due to their lower prevalence, PAB 
are less attractive serologic marker for Crohn’s disease 
compared to ASCA. Autoantibodies against intestinal 
goblet cells (GAB) are present in about one third of pa-
tients with Crohn’s disease and ulcerative colitis  [12] . 
 Despite intense research during the last years, the im-
plication of these serum antibodies in infl ammatory bow-
el disease remains enigmatic. ASCA  [1] , p-ANCA  [6, 13] 
and GAB  [12] are found in increased prevalence also in 
fi rst degree relatives of patients with infl ammatory bowel 
disease, in particular if the index patient displays the re-
spective antibody. PAB were also associated with the oc-
currence of infl ammatory bowel disease in fi rst-degree 
relatives of patients with Crohn’s disease  [14] . On the 
other hand, fi rst-degree relatives of patients with infl am-
matory bowel disease display an increased disease suscep-
tibility compared to the general population and, thus, it 
has been hypothesized that the aforementioned serum 
markers might represent enhanced genetic or environ-
mental disease susceptibility  [15] . However, if this as-
sumption is correct, one would expect that antibody-pos-
itive fi rst-degree relatives are more likely to develop in-
fl ammatory bowel disease than antibody-negative 
fi rst-degree relatives. The present study addressed this is-
sue by comparing the number of incident cases of Crohn’s 
disease and ulcerative colitis in a cohort of fi rst-degree 
relatives of patients with infl ammatory bowel disease af-
ter a follow-up period of 7 years. 
 Patients and Methods 
 Twenty-fi ve patients with Crohn’s disease, 19 patients with ul-
cerative colitis and 102 fi rst-degree relatives in whom presence of 
ASCA, p-ANCA, PAB and GAB had been assessed were enrolled 
in this study. ASCA IgA and ASCA IgG have been detected by 
ELISA (Medizym, for details, see ref.  [1] ) whereas for the remainder 
of antibodies indirect immunofl uorescence had been performed as 
described in detail elsewhere  [11, 12] . Seven years after collection 
of serum samples, fi rst degree-relatives were interviewed applying 
a standardized questionnaire, which assessed the following symp-
toms: Diarrhea of more than three days duration, anal discharge of 
mucus or blood, weight loss, abdominal pain, ocular infl ammation, 
cutaneous nodules or ulcerations and arthralgias. Additionally, in 
case of newly diagnosed infl ammatory bowel disease the medical 
charts were reviewed. The diagnosis of Crohn’s disease or ulcer-
ative colitis was based on conventional clinical, endoscopic, histo-
pathologic and radiological criteria. We aimed to contact all rela-
tives. If this was not possible, family members were asked about 
the fate of relatives who took not part in this study. Antibody-pos-
itive and antibody-negative fi rst-degree relatives were compared in 
terms of number of incident cases with infl ammatory bowel disease 
at 7 years after storage of serum samples. Statistical evaluation was 
carried out using Fisher’s exact test. 
 Results 
 A total of 40 families with one affected individual and 
2 families with 2 affected individuals were included in 
the study. In 11 of the 42 families, one unaffected fi rst-
degree relative per family was enrolled. In 12 families 2, 
in 13 families 3, and 4 and 5 fi rst-degree relatives were 
enrolled in 2 and 4 families, respectively. The baseline 
and clinical characteristics of index patients and the de-
mographics of fi rst-degree relatives are depicted  in tables 
1 and  2 , respectively. 
 Of the 25 patients with Crohn’s disease, 9 patients 
were positive for ASCA IgG (5 of them displayed also 
ASCA IgA), 10 patients were positive for PAB, 6 patients 
displayed GAB and 1 patient was positive for p-ANCA. 
Eight of the 25 patients included in this study were posi-
 Table 1. Demographics and clinical charac-
teristics of index patients with infl amma-
tory bowel disease 
Crohn’s disease (n = 25)
Gender, male/female 8/17
Age, mean (range) 43 (29–66)
Disease location1
Ileal and no colonic 2
Colonic and no ileal 2
Ileocolonic disease 17
Disease behavior1
Fistulizing 14
Fibrostenotic 15
Nonfi stulizing 2
Nonfi brostenotic
Ulcerative colitis (n = 19)
Gender, male/female 6/13
Age, mean (range) 50 (34–64)
Disease location1
Pancolitis 4
Left-sided colitis 6
Proctitis 2
1 Extended phenotypic information was 
available for 21 of 25 patients with Crohn’s 
disease and 12 of 19 patients with ulcerative 
colitis, respectively.
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tive for more than one of the antibodies tested. Of the 19 
patients with ulcerative colitis 7 were positive for p-
ANCA and 10 patients displayed GAB. Of these, three 
were positive for both p-ANCA and GAB ( table 3 ). 
 Among fi rst-degree relatives of patients with infl am-
matory bowel disease, 34 of 102 (33%) were positive for 
at least one of the studied serum antibodies (13 for ASCA 
IgA, ASCA IgG or both, 3 for p-ANCA, 3 for PAB and 
17 for GAB) ( table 3 ). In 2 fi rst-degree relatives, more 
than one serum antibody was detectable, one of them was 
positive for both GAB and ASCA IgG and the other dis-
played GAB and p-ANCA. One new case of Crohn’s dis-
ease and one new case of ulcerative colitis were diagnosed 
in the group of fi rst-degree relatives during the follow-up 
period. In both cases the diagnosis was concordant with 
the respective index patient, which means that the patient 
and the relative displayed the same type of infl ammatory 
bowel disease. However, both relatives did not display 
any of the investigated serum antibodies (p = 1 compared 
to unaffected relatives). In the remainder of fi rst-degree 
relatives, symptoms suggestive of yet undiagnosed in-
fl ammatory bowel disease were not detected. 
 Discussion 
 Previous studies showed occurrence of various anti-
bodies such as p-ANCA  [6, 13] , ASCA  [1] , antibodies 
against endothelial cells  [16] or antinuclear antibodies 
 [17] not only in patients with Crohn’s disease or ulcer-
Gender
male/female
Mean age 
(range)
New cases
of IBD
Parents of patients with
Crohn’s disease (n = 26) 13/13 66 (55–84) –
Ulcerative colitis (n = 18) 8/10 70 (64–80) 1
Siblings of patients with
Crohn’s disease (n = 10) 4/6 43 (27–61) –
Ulcerative colitis (n = 17) 8/9 41 (31–50) –
Children of patients with
Crohn’s disease (n = 16) 8/8 28 (13–46) 1
Ulcerative colitis (n = 15) 8/7 27 (16–37) –
 
 Table 2. Demographics of fi rst-degree 
 relatives of patients with infl ammatory 
bowel disease 
Number of individuals tested positive for
serum antibodies
ASCA IgA ASCA IgG pANCA PAB GAB
Patients
Crohn’s disease (n =25) 5 9 1 10 6
Ulcerative colitis (n = 19) – – 7 – 10
First-degree relatives parents of patients with
Crohn’s disease (n = 26) 4 2 – 1 1
Ulcerative colitis (n = 18) 2 1 – – 2
Siblings of patients with
Crohn’s disease (n = 10) 2 – – 1 1
Ulcerative colitis (n = 17) – – – – 4
Children of patients with
Crohn’s disease (n = 16) 1 – 1 1 4
Ulcerative colitis (n = 15) 1 – 2 – 5
 
 Table 3. Prevalence of serum antibodies 
in index patients with infl ammatory bowel 
disease and their fi rst-degree relatives 
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ative colitis, but also in their still healthy fi rst-degree rel-
atives, who display a signifi cantly increased risk to de-
velop infl ammatory bowel disease. Therefore, an implica-
tion of these antibodies in infl ammatory bowel disease 
comprises their use as potential markers of disease sus-
ceptibility. In line with this concept is the observa - 
tion that infl ammatory bowel disease-specifi c antibodies 
are – with few exceptions, such as endothelial cell anti-
bodies  [16] – not found in increased prevalence in infec-
tious enterocolitis  [1] or in spouses of patients  [17] . How-
ever, due to the lack of long-term follow-up data about 
the course of antibody-positive fi rst-degree relatives, the 
potential role of these serum markers in refl ecting disease 
susceptibility still remains speculative so far. The results 
of our study do also not sustain this hypothesis, although 
this is, to the best of our knowledge, the fi rst approach 
addressing the issue. However, our retrospective study 
bears some limitations: First-degree relatives with an un-
remarkable history were offered a screening colonoscopy 
if they were older than 50 years, but in the remainder an 
endoscopic investigation was not performed due to ethi-
cal reasons. Thus, only 25 of the 102 fi rst-degree relatives 
underwent colonoscopy during the follow-up period. 
With the exception of the two newly diagnosed cases with 
infl ammatory bowel disease no signs compatible with yet 
undiagnosed Crohn’s disease or ulcerative colitis were 
observed in this group. However, comparable to previous 
trials assessing the presence of ASCA in patients with 
HLA-B27 associated spondylarthropathies  [8, 9] , we can-
not rule out that subclinical cases of infl ammatory bowel 
disease might have been missed in the remainder of fi rst-
degree relatives. A potential observation bias could result 
from the fact that we might have missed relatives who 
were not able or willing to take part in the study. In ad-
dition, the follow-up period might have been too short, 
and this study will probably have to be repeated in an 
extended population within a few years. Whether serum 
markers are associated with specifi c clinical phenotypes 
in infl ammatory bowel disease, remains a matter of ongo-
ing research  [18–20] . However, it is possible, that certain 
subtypes of Crohn’s disease or ulcerative colitis which 
predispose to the presence of serum antibodies were un-
derrepresented in the population studied herein. Finally, 
it should be pointed out that at least in our hands, two of 
the investigated antibodies namely p-ANCA and PAB, 
did not show a familial occurrence  [11] , which is in the 
case of p-ANCA in accordance with the majority of lit-
erature data [for overview, see  21] . To the best of our 
knowledge, PAB were never reported to occur familial. 
Nevertheless, PAB were regarded in the analysis due to 
the observation of some antibody-positive fi rst-degree 
relatives which seem to be prone to develop Crohn’s dis-
ease  [14] . The frequencies of serum antibodies in healthy 
unrelated controls ranged between 2 and 4%  [1, 11, 12] 
and the latter were not included in the present trial. 
 In summary, our retrospective pilot study does not 
sustain the putative role of serum antibodies as markers 
of disease susceptibility in infl ammatory bowel disease. 
The fact that none of the antibody-positive relatives de-
veloped clinical symptoms of infl ammatory bowel dis-
ease is reassuring. However, due to the above mentioned 
limitations these data certainly have to await confi rma-
tion in larger, ideally prospectively designed multi-centre 
trials before defi nitive conclusion can be drawn. 
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